Repligen (RGEN) Lifted to “Strong-Buy” at BidaskClub

BidaskClub upgraded shares of Repligen (NASDAQ:RGEN) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday morning.

A number of other research firms have also recently commented on RGEN. Zacks Investment Research raised Repligen from a hold rating to a buy rating and set a $62.00 target price on the stock in a research note on Thursday, October 4th. Janney Montgomery Scott reaffirmed a buy rating on shares of Repligen in a research note on Thursday, October 4th. JPMorgan Chase & Co. upped their target price on Repligen to $60.00 and gave the company an overweight rating in a research note on Monday, September 24th. HC Wainwright assumed coverage on Repligen in a research note on Wednesday, September 26th. They set a neutral rating and a $49.00 target price on the stock. Finally, Citigroup upped their target price on Repligen from $45.00 to $56.00 and gave the company a buy rating in a research note on Friday, July 20th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $51.86.

Shares of RGEN traded up $1.26 during mid-day trading on Tuesday, reaching $57.77. 3,972 shares of the company’s stock traded hands, compared to its average volume of 430,971. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of 83.42, a P/E/G ratio of 4.63 and a beta of 0.69. Repligen has a 12 month low of $29.56 and a 12 month high of $58.99.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, August 2nd. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). The business had revenue of $47.73 million for the quarter, compared to the consensus estimate of $45.84 million. Repligen had a net margin of 13.49% and a return on equity of 5.05%. The company’s quarterly revenue was up 47.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 EPS. As a group, sell-side analysts expect that Repligen will post 0.71 EPS for the current year.

In other Repligen news, major shareholder Roy T. Eddleman sold 33,142 shares of the company’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $49.05, for a total transaction of $1,625,615.10. Following the completion of the sale, the insider now owns 413,985 shares in the company, valued at $20,305,964.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Anthony Hunt sold 27,566 shares of the company’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $57.71, for a total value of $1,590,833.86. Following the sale, the chief executive officer now owns 255,017 shares of the company’s stock, valued at approximately $14,717,031.07. The disclosure for this sale can be found here. In the last three months, insiders sold 88,884 shares of company stock worth $4,693,683. 1.40% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in Repligen during the second quarter worth $135,000. Seven Eight Capital LP purchased a new stake in Repligen during the third quarter worth $217,000. Smith Asset Management Group LP lifted its holdings in Repligen by 1,511.8% during the second quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock worth $219,000 after buying an additional 4,369 shares during the period. Benin Management CORP purchased a new stake in Repligen during the second quarter worth $235,000. Finally, GSA Capital Partners LLP purchased a new stake in Repligen during the second quarter worth $250,000. Institutional investors own 92.50% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Recommended Story: Hedge Funds

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply